AusCann Group Holdings

What AusCann Group Holdings does

AusCann Group Holdings Limited (ASX: AC8) is an Australian-listed pharmaceutical company headquartered in West Perth that develops and commercialises standardised, GMP-manufactured cannabinoid-derived therapeutics for human and animal health. Its technical platform centres on novel drug-delivery technologies and reproducible formulations that meet ICH, PIC/S, and EU GMP standards audited by TGA, FDA, WHO, and SAHPRA. The active portfolio includes the human therapies CannEpil and CogniCann (manufactured at ECC Pharm in North Macedonia and distributed via early patient access programs in Ireland, the UK, and Germany) and the veterinary candidate CPAT-01, covered by a US patent (extended to July 2041) for a THC/CBD liquid composition treating canine pain.

The business operates primarily through non-consolidated associates and partnerships rather than direct sales. AusCann holds a 19.8% equity stake in European Cannabis Corporation Limited (ECC), which operates EU-GMP cultivation in Spanchevo, an extraction facility in Skopje, and a German pharmaceutical distribution business in Dortmund. ECC's subsidiary RH Pharma holds two pending Polish supply agreements valued at EUR 1.5 million per annum each and completed a EUR 700,000 THC flower sale. AusCann also retains a 48% free-carried interest in CannPal Animal Therapeutics, whose CPAT-01 program is in a Phase 2C dose confirmation study ahead of an FDA-CVM filing. Distribution is overwhelmingly prescription- and HCP-driven: through the TGA Special Access Scheme and Authorised Prescriber pathways in Australia, via early patient access programs in the EU, and through licensing partnerships globally.

The company is in active corporate restructuring. It signed a binding term sheet in August 2025 to sell AC8 operating assets to Argent BioPharma (ASX: RGT), with a streamlined acquisition announcement in January 2026, while also exploring an amalgamation with ECC. Revenue at the parent level is not publicly disclosed; commercial cashflows for the parent run primarily through licensing royalties and equity-method earnings from ECC and CannPal rather than consolidated product sales.

Name

AusCann Group Holdings

Legal name

AusCann Group Holdings Limited

Website

https://auscann.com.au

Company type

Public

Founded year

1986

Operating status

Operating

Headcount range

1–10 employees

Short description

AusCann Group Holdings (ASX: AC8) is an Australian-listed pharmaceutical company developing standardised, GMP-manufactured cannabinoid-derived therapeutics for human and animal health, primarily through its 19.8% stake in European Cannabis Corporation and its 48% interest in CannPal Animal Therapeutics.

Ownership category

akta.pro rank

Product category

Cannabinoid Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Smoking Cessation & Nicotine Replacement Therapy (Gum, Patches, Lozenges) (CRADAMAI)

akta.pro secondary industry

CBD/Hemp Pet Products Retail (CRANAHAF)

Keywords

• Cannabinoid therapeutics
• Pharmaceutical manufacturing
• Veterinary medicines
• GMP certified production
• Drug delivery technology

Headquarters

HQ city

Perth

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Commercialisation of cannabinoid-derived therapeutic products for humans and animals through various regulatory frameworks globally
2. Licensing Royalties: Revenue from licensing CannPal's proprietary cannabinoid formulations and dermatology assets to global partners. AusCann retains 48% free-carried interest in CannPal.
3. Manufacturing Services: ECC Pharm provides manufacturing and batch release services for cannabinoid therapies including CannEpil and CogniCann under GMP standards
4. Supply Agreements: ECC Pharm generates revenue through supply agreements including two Polish companies worth 1.5m EUR per annum each for cannabis flower and extracts

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

AusCann develops and commercialises standardised cannabinoid-derived therapeutic products for humans and animals, including prescription cannabinoid therapies (CannEpil, CogniCann) and animal health treatments (CPAT-01). The company operates GMP-certified pharmaceutical manufacturing through its ECC partnership, uses innovative drug delivery technologies to enhance novel cannabinoid formulations, and distributes products through regulatory pathways such as TGA Special Access Scheme, Authorised Prescriber schemes, and early patient access programmes in the EU.

Product overview

AusCann Group Holdings is an Australian-based company focused on the development and commercialisation of cannabinoid-derived therapeutic products for humans and animals. The company operates primarily through subsidiaries and partnerships, including: CannPal Animal Therapeutics (animal health subsidiary), which is developing CPAT-01 for canine pain; and manufacturing partnerships through ECC Pharm/RH Pharma for human products including CannEpil® and CogniCann® (cannabinoid therapies). The portfolio spans human and veterinary pharmaceuticals, with products in early patient access programs in Europe and drug candidates in clinical development for FDA-CVM registration.

Differentiator

Problem solved

Functional benefit

Brands

• CPAT-01: CannPal's novel cannabinoid-based veterinary treatment for pain in dogs, currently in development for FDA-CVM registration.
• CannPal Animal Therapeutics

Products and services

• CannEpil CannEpil is a pioneering cannabinoid therapy for human patients manufactured under EU GMP standards by ECC Pharm and made available through early patient access programs in key EU countries including Ireland, the UK, and Germany.
• CogniCann CogniCann is a pioneering cannabinoid therapy for human patients manufactured under EU GMP standards by ECC Pharm and made available through early patient access programs in key EU countries including Ireland, the UK, and Germany.
• CPAT-01 CPAT-01 is CannPal's novel cannabinoid-based veterinary treatment for pain in dogs, currently in development for FDA-CVM registration with a Phase 2C dose confirmation study underway.
• CannPal Dermatology Assets Innovative plant-based dermatology assets for animal health, with North American commercial rights acquired by a leading global animal health partner through CannPal.

Quantifiable outcome

• Oral administration of cannabinoid formulation achieves sufficient bioavailability without significant adverse events

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Argent BioPharma LimitedcoreStrategic or Co-development Partner · 5 March 2025Strategic manufacturing partnership where ECC takes on full manufacturing and batch release responsibilities for Argent BioPharma's CannEpil and CogniCann cannabinoid therapies for early patient access programs in EU countries including Ireland, UK, and Germany. Technology transfer to ECC's North Macedonia facility.
• Neurotech International LimitedcoreStrategic or Co-development Partner · 13 February 2025Binding Development Agreement with RH Pharma (subsidiary of ECC). Neurotech will leverage ECC's capabilities in product development, manufacturing, and scale-up for cannabis-based pharmaceuticals. RH Pharma will undertake controlled recombination of highly purified cannabinoids into broad-spectrum cannabinoid drug products meeting global regulatory standards.
• European Cannabis Corporation (ECC)coreStrategic or Co-development Partner · 1 January 2024AusCann converted loan to ECC Pharm to equity, now owns 19.8% of ECC. ECC operates EU GMP certified medicinal cannabis growth facility in Spanchevo, Macedonia, extraction facility in Skopje, and pharmaceutical distribution business in Dortmund, Germany.
• RH PharmacoreTechnology or Integration · 1 January 2024ECC's 100% owned subsidiary that continues towards commercialisation with significant increase in inbound interest. Completed second material sale of EUR 700,000 high grade THC Flower. Signed supply agreements with two Polish companies expected to bring EUR 1.5m per annum each.
• CannPal Animal Therapeutics LtdcoreStrategic or Co-development Partner · 1 January 2021AusCann divested animal health assets to CannPal in 2021, retaining 48% free-carried interest. CannPal secured deal with global market leading animal health company for CPAT-01 development and commercialisation in Europe and North America, plus North American rights to dermatology assets.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Incannex Healthcare: ASX-listed clinical-stage pharmaceutical company developing cannabinoid-based psychedelic-assisted and combination therapies. Comparable on Australian-listed pharmaceutical development of cannabinoid-derived treatments through regulated clinical pathways.
• GW Pharmaceuticals (Jazz Pharmaceuticals): Pioneer in cannabinoid-derived prescription pharmaceuticals (Sativex, Epidiolex); acquired by Jazz Pharmaceuticals in 2021. Direct comparable for AusCann's CannEpil/CogniCann human cannabinoid therapeutics pipeline targeting epilepsy and neurological conditions.
• MediPharm Labs: GMP-certified cannabis concentrate manufacturer supplying pharmaceutical-grade cannabis products internationally. Comparable as a contract cannabinoid pharmaceutical manufacturer with EU GMP credentials, similar to ECC Pharm's model.
• Zelira Therapeutics: Clinical-stage cannabinoid pharmaceutical company developing prescription medicines for chronic pain, insomnia and autism. Direct comparable on pharmaceutical-grade, clinically validated cannabinoid formulations targeting unmet medical needs.
• Althea Group Holdings: Australian-based medicinal cannabis pharmaceutical company focused on production, distribution and education for healthcare professionals. Most direct Australian peer to AusCann in patient access programs and cannabinoid-based medicines for chronic conditions.

Regional players

• Bod Australia: Australian-listed medicinal cannabis and hemp skincare company; shares the Australian-listed micro-cap cannabinoid pharma space and several former Bod Australia executives (including the CFO) overlap with AusCann leadership.

Broad incumbents

• Aurora Cannabis: Canadian licensed producer with EU GMP certified cultivation and medical cannabis distribution across Europe including Germany. Comparable through EU GMP manufacturing and German distribution presence mirroring ECC's footprint.
• Jazz Pharmaceuticals: Specialty pharmaceutical company that owns GW Pharmaceuticals' cannabinoid-derived Epidiolex franchise. Comparable as a pharma acquirer of cannabinoid therapeutics and as the largest commercial validator of prescription cannabinoid medicines globally.
• Tilray Brands: Global cannabis leader with pharmaceutical-grade cultivation, GMP manufacturing and EU distribution. Comparable through its EU GMP manufacturing footprint and medical/pharmaceutical cannabis portfolio that competes for the same patient access channels.

Others

• Argent BioPharma: ASX-listed cannabinoid pharmaceutical company and current acquirer of AusCann's AC8 assets. Comparable as an adjacent listed player in cannabinoid-based therapies for neurological conditions (CannEpil, CogniCann) and direct counterparty in AusCann's restructuring transactions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/auscannau
• LinkedInlinkedin.com/company/tasman-health-cannabinoids-pty-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AusCann Group Holdings